Introduction
The 34th World Congress on Heart Diseases was an international gathering of cardiology professionals, researchers, clinicians, and public health advocates that convened to share the latest scientific discoveries, clinical innovations, and policy recommendations related to cardiovascular disease. The congress, held in Geneva, Switzerland, attracted over 4,000 participants from more than 80 countries. It served as a platform for dialogue across disciplines, from basic science to patient care, and reinforced global commitments to reduce the burden of heart disease through collaborative research and health system strengthening.
History and Background
Origins of the World Congress on Heart Diseases
The World Congress on Heart Diseases originated in the early 1980s as a series of biennial meetings organized by the International Society of Cardiology (ISC). Its founding purpose was to foster international cooperation in cardiovascular research and to disseminate evidence-based practices to clinicians worldwide. Over the decades, the congress evolved in scale, scope, and influence, reflecting advances in imaging, pharmacotherapy, and interventional techniques.
Previous Congresses
Each iteration of the congress has built upon the previous ones. The 33rd Congress, held in São Paulo in 2018, emphasized the importance of early detection and highlighted the growing prevalence of cardiovascular disease in low‑ and middle‑income countries. The 32nd Congress in Tokyo in 2016 focused on emerging technologies such as wearable devices and artificial intelligence for risk stratification. These themes set the stage for the 34th Congress, which integrated a broader view of heart disease prevention, treatment, and policy.
Organization of the 34th Congress
The 34th Congress was organized by the ISC in collaboration with the World Heart Federation (WHF) and the European Society of Cardiology (ESC). The planning committee comprised representatives from cardiology societies across six continents, ensuring a balance between clinical practice and research perspectives. The event was scheduled from 12 to 17 September 2025, incorporating a mix of plenary sessions, workshops, poster sessions, and symposia.
Themes and Keynote Topics
Cardiovascular Pathophysiology
Keynote presentations delved into the molecular mechanisms underlying atherosclerosis, heart failure, and arrhythmias. Discussions included the role of inflammation in plaque instability, the contribution of cardiac remodeling to heart failure progression, and the electrophysiological alterations that predispose patients to atrial fibrillation. The sessions also highlighted the influence of genetic predisposition and environmental factors on disease development.
Innovative Therapies
The congress showcased breakthroughs in drug development and interventional cardiology. Novel pharmacologic agents such as selective endothelin receptor antagonists and gene‑editing approaches for familial hypercholesterolemia were reviewed. In interventional cardiology, the introduction of biodegradable stent platforms and refined transcatheter aortic valve replacement (TAVR) techniques were presented. Dedicated workshops on precision medicine illustrated how patient‑specific factors can guide therapeutic decisions.
Public Health Initiatives
Public health panels addressed strategies for reducing cardiovascular risk at the population level. Topics included tobacco control policies, salt reduction campaigns, and the integration of cardiovascular screening into primary care systems. Speakers from ministries of health and non‑governmental organizations shared lessons learned from large‑scale prevention programs in various regions.
Proceedings and Contributions
Sessions
The congress featured 18 plenary sessions and 32 breakout symposia. Each session attracted a range of participants, from seasoned cardiologists to early‑career scientists. Sessions were categorized into clinical cardiology, cardiovascular imaging, interventional cardiology, pharmacotherapy, and cardiovascular public health.
Papers and Posters
Over 600 research papers were presented, encompassing randomized controlled trials, cohort studies, and basic science investigations. In addition, 1,200 poster presentations provided a forum for emerging investigators to discuss preliminary findings. Topics spanned myocardial ischemia mechanisms, novel biomarkers, and the impact of socioeconomic determinants on cardiovascular outcomes.
Clinical Trials Presented
Several large clinical trials were introduced, including the Global Heart Failure Outcomes Study (GHFO) and the International Coronary Intervention Safety Trial (ICIST). The GHFO, a multicenter, double‑blind, placebo‑controlled trial, evaluated the efficacy of a novel cardioprotective agent in patients with heart failure with reduced ejection fraction. ICIST assessed the safety and efficacy of a new antithrombotic regimen in patients undergoing percutaneous coronary intervention worldwide.
Notable Attendees and Speakers
Principal Speakers
Prominent cardiology leaders addressed the congress, including the President of the ESC, the Chair of the WHF, and the Chair of the ISC. Additional distinguished speakers comprised heads of national health ministries, Nobel laureates in cardiovascular research, and pioneers of minimally invasive cardiac surgery. Their talks underscored the global significance of collaborative research and policy action.
Emerging Researchers
Young investigators were highlighted through the “Future of Cardiology” award, given to five doctoral candidates whose work showed promise in areas such as regenerative medicine, telemedicine, and artificial intelligence. These awardees presented at dedicated sessions and received mentorship opportunities to further develop their research agendas.
Impact and Outcomes
Scientific Advancements
The congress contributed to several knowledge breakthroughs, including the identification of a new lipid‑related genetic variant associated with coronary artery disease risk and the validation of a novel imaging biomarker for early detection of myocardial fibrosis. These findings have been subsequently incorporated into clinical guidelines and ongoing research projects.
Policy Influence
Policy sessions culminated in a joint statement endorsed by the ISC, WHF, and ESC. The statement advocated for the inclusion of cardiovascular screening in universal health coverage packages, the implementation of evidence‑based antithrombotic therapy protocols, and the establishment of global registries for cardiovascular outcomes. The document has been cited by national governments in drafting health policy reforms.
Educational Outreach
Workshops and interactive modules were offered to clinicians from low‑resource settings, focusing on the use of affordable diagnostic tools and guideline‑directed therapy. The congress also launched an online education portal that provided access to session recordings, slide decks, and curated literature for continuous professional development.
Criticisms and Challenges
Funding and Sponsorship
Some participants expressed concerns regarding the influence of industry sponsorship on session content. While the ISC maintained that all presentations underwent rigorous peer review, calls for increased transparency persisted. In response, the congress introduced a declaration of interests policy and restricted advertising within the conference venue.
Accessibility and Inclusivity
Despite efforts to attract a diverse audience, representation from sub‑Saharan Africa and South America remained below 15 percent. Critics highlighted barriers such as visa restrictions, travel costs, and language limitations. The ISC announced subsequent initiatives to provide travel grants and multilingual support to address these gaps.
Future Directions
Planned Next Congress
The 35th World Congress on Heart Diseases is scheduled to take place in Tokyo in 2027. Anticipated themes include precision cardiology, the role of microbiome in cardiovascular health, and the integration of digital health technologies into routine care. The organizing committee has set a goal of expanding participant numbers by 20 percent and enhancing regional representation.
Long‑Term Strategic Goals
Aligned with the World Health Organization’s Sustainable Development Goals, the ISC and partner societies aim to reduce the global cardiovascular mortality rate by 25 percent over the next decade. Strategic initiatives involve establishing regional cardiovascular research hubs, promoting data sharing across borders, and fostering interdisciplinary collaborations that span basic science, clinical practice, and public health.
No comments yet. Be the first to comment!